Valruzia

[Aethan]

NOVA Pharma announces cure against rabies

Still in Phase III, the vaccine would prevent the fatal ending, although with some secondary effects

October 5655

Wiktoria Kominek, director of the Valruzian National Centre for Scientific Research

---

In what may become a historic breakthrough for global medicine, Valruzia’s state pharmaceutical company NOVA Pharma has announced the successful development of a vaccine-based therapeutic cure for rabies, a disease that has remained virtually untreatable once clinical symptoms appear. The announcement, made jointly with the Valruzian National Centre for Scientific Research (NCBN by his acronym in Valruzian), marks a milestone in the quest to neutralize one of the deadliest known viral infections, and places Valruzia at the forefront of the scientific research in terms of novel vaccine development and diseases research.

The new compound, named Rabiocid-V, is currently undergoing Phase III clinical trials, but preliminary results have shown extraordinary efficacy in halting disease progression in infected individuals, even after the onset of early neurological symptoms - a stage traditionally regarded as irreversible.

"This is not just a vaccine; it’s what it also means, that hopefully will boost our research in the cure of other diseases such as AIDS"

said Dr. Wiktoria Kominek, director of the NCBN, during the official press conference in Nowogard.

"For the first time in recorded medical history, we are seeing real possibilities of reversing early-stage rabies infection in humans, which until now had a near-100% fatality rate once symptons appeared"

.

The discovery is the result of an intensive ten-year research program led by the NCBN’s Virology and Neurological Diseases Department, in collaboration with multiple regional universities and field hospitals. Once the experimental compound reached proof-of-concept stage, it was transferred to NOVA Pharma, which has since taken the lead in scaling up production and navigating the regulatory pathway.

"This is the model Valruzia has championed for decades: research focused on public interest, supported by public institutions"

stated Karol Sawicki, executive director of NOVA Pharma.

"Our job now is to validate safety, prepare for mass production, and engage with international partners for broader access"

.

What is rabies?

Rabies is a viral disease produced by the rabies virus (Family Rhabdoviridae) that causes encephalitis in humans and other mammals transmitted mainly through saliva of those animal infected by the disease, with no confirmed cases of human-to-human transmission. Its symptoms vary but include fever and abnormal sensations at the site of exposure, followed by nauseas, vomiting, spams, uncontrolled emotions, fear of water, body paralysis, confusion, and loss of consciousness. Once symptoms appear, the result is virtually always death, at least until now.

"Previously, when symptoms appeared, one could only give pain-relief treatments and hope for the best, which in many cases was just a quick death. Now, we are on the verge of changing that for many, many people around Terra."

How does this vaccine work?

According to NOVA PHarma and NCBN  officials, the treatment consists of a multi-component injection combining a modified rabies glycoprotein vector with neuroinflammation inhibitors and RNA-based immunostimulants. Administered in two stages, it targets both the viral replication cycle and the immune system’s dysregulated response, aiming to block the virus’s progression through the central nervous system.

Phase III trials have been conducted on 156 human volunteers from controlled exposure contexts in coordination with humanitarian missions abroad. So far, no fatalities have been reported among treated individuals. However, mild to moderate secondary effects - including fever, joint inflammation, and temporary disorientation and loss of limb mobility - have been observed in over 65% of participants.

"We are cautiously optimistic"

Dr. Kominek added.

"While the treatment isn’t yet perfect, it’s far beyond anything we've ever had in the arsenal against rabies. And certainly, fever and joint inflammation are better outcomes than death".

Chancellor Zuzanna Kosowska has praised the "relentless work of Valruzian scientists and the historic role of our public sector in defending human life", while also giving credit to Chancellor Szymon Nowik, himself a microbiologist, for his initiative to build both NOVA Pharma and the NCBN.

Experts foresee a potential diplomatic ripple effect as the Valruzian government, through NOVA Pharma, begins talks with key global partners to explore licensing and joint production agreements. Already, preliminary negotiations have begun with several countries, particularly those in rabies-endemic regions, to become the first recipients of the much-wanted vaccine.

If Phase III trials continue to show positive outcomes, NOVA Pharma expects to initiate Phase IV by mid-5656, involving a broader and more demographically diverse cohort. In parallel, the Health Ministry is already preparing a strategic stockpile, in case of rapid domestic deployment.